Fig. 2.
Cumulative incidence of relapse.
Cumulative incidence of relapse for patients receiving no postremission therapy, standard-dose cytarabine therapy, high-dose cytarabine (HiDAC) therapy.
Cumulative incidence of relapse.
Cumulative incidence of relapse for patients receiving no postremission therapy, standard-dose cytarabine therapy, high-dose cytarabine (HiDAC) therapy.
